Donna Ryan, MD, FTOS; Robert F. Kushner, MD; A. Michael Lincoff, MD; et al.
ObesityWeek 2024 – Oral presentation
Key messages
- In the SELECT trial, semaglutide delivered CV benefits in patients with overweight or obesity, establishing these conditions as modifiable risk factors.
- Recent findings highlight potential in broader indications including kidney disease and inflammation, with particularly promising results for prediabetes.
- Long-term safety findings are consistent with findings for other GLP-1RA.
